Conatumumab

BIOLOGICAL4 trials

Sponsors

Amgen, Radiation Therapy Oncology Group, TetraLogic Pharmaceuticals

Conditions

Advanced Solid TumorsCarcinoidColon CancerColorectal CancerLocally AdvancedLymphomaMetastatic CancerMetastatic Colorectal Cancer

Phase 1

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

CompletedNCT00630786

AmgenColon Cancer, Colorectal Cancer, Metastatic Colorectal Cancer +2

Start: 2008-01-31End: 2010-11-30Updated: 2014-02-06

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

WithdrawnNCT01017822

Radiation Therapy Oncology GroupPancreatic Cancer

Updated: 2013-06-24

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

CompletedNCT01940172

TetraLogic PharmaceuticalsRelapsed Epithelial Ovarian Cancer, Relapsed Fallopian Tube Cancer, Relapsed Primary Peritoneal Cancer

Start: 2013-11-30End: 2015-12-31Updated: 2016-01-14

Phase 2

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

CompletedNCT01327612

AmgenAdvanced Solid Tumors, Carcinoid, Colorectal Cancer +6

Start: 2011-03-03End: 2020-02-05Updated: 2021-02-21

Related Papers

A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Journal of Clinical Oncology2015-05-207 citations